Reneuron Gp (RNUGF) Rating Lowered to Hold at Zacks Investment Research

Reneuron Gp (OTCMKTS:RNUGF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday.

According to Zacks, “ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom. “

Shares of Reneuron Gp (RNUGF) opened at $0.02 on Friday. Reneuron Gp has a 52 week low of $0.02 and a 52 week high of $0.05.

ILLEGAL ACTIVITY WARNING: This article was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.chaffeybreeze.com/2018/01/06/reneuron-gp-rnugf-rating-lowered-to-hold-at-zacks-investment-research.html.

Reneuron Gp Company Profile

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company’s lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes.

Receive News & Ratings for Reneuron Gp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneuron Gp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply